Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the presentation of four posters evaluating HLP003, its investigational oral deuterated psilocin analog being developed as an adjunctive treatment for major depressive disorder (MDD), at Psych Congress 2026 in New Orleans. The presentations highlight the company's progress in developing a novel treatment option for a condition that affects millions worldwide.
Three of the posters build on the company's completed Phase 1/2a randomized, double-blind study. They include 12-month efficacy results, analyses of anhedonia and the psychedelic experience, and expanded safety data. These long-term data are critical for understanding the durability of treatment effects and the overall risk-benefit profile of HLP003. Anhedonia, the inability to feel pleasure, is a core symptom of MDD that often responds poorly to existing therapies, making these analyses particularly relevant for patients with difficult-to-treat depression.
Helus Pharma also presented a trial-in-progress overview of PARADIGM, its ongoing Phase 3 clinical program evaluating the efficacy and safety of HLP003 as an adjunctive treatment for MDD. The Phase 3 program represents a pivotal step toward potential regulatory approval and commercialization. HLP003 has already received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status designed to expedite the development and review of drugs that may offer substantial improvement over existing therapies.
The implications of this announcement extend beyond Helus Pharma. For the psychedelic and cannabis industries, it signals continued clinical validation of serotonergic agonists as mainstream psychiatric treatments. HLP003 is a proprietary novel serotonergic agonist (NSA), a synthetic molecule designed to activate serotonin pathways believed to promote neuroplasticity. Unlike classic psychedelics, NSAs aim to provide therapeutic benefits with potentially better tolerability and scalability. If approved, HLP003 could offer a new adjunctive option for MDD, addressing the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs. In addition to HLP003, the company is developing HLP004, also a proprietary NSA, in Phase 2 for generalized anxiety disorder. Helus Pharma has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland.
For investors and industry observers, the presentation at Psych Congress 2026 underscores Helus Pharma's leadership in the psychedelic pharmaceutical space. The company's focus on rigorous clinical development and long-term data collection may set a benchmark for others in the sector. As the mental health crisis continues to grow, innovations like HLP003 could play a significant role in expanding treatment options and improving outcomes for patients. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. To view the full press release, visit https://ibn.fm/R2a0h. For more information about Helus Pharma, visit www.helus.com.
